Many Patients Stop Using Weight-loss Drugs Within A Year, Reveals Data

Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply

Novo Nordisk’s Obesity Drug Pipeline Stacked Up For Next 15-20 Yrs: John C Dawber, GBS

In India, the Danish drugmaker Novo Nordisk is the market leader and presently meets over 60 per cent of the country’s insulin supply. Speaking to BW Businessworld in an exclusive interaction, John C. Dawber, CVP and MD, Global Business Services talks about the company’s GLP1 growth story, the market of obesity drugs and their safety profile, building capacities and the company's future ambitions in India

Europe Will Lose Out On Medical Innovation Unless Draft Rules Change: Novo Nordisk CEO

The European Commission will present its proposed overhaul of the bloc's pharmaceuticals regulation on March 29, the first major revisions to medicines rules in 20 years. It says drugs need to reach patients more quickly and in all European nations

Most Top-selling Drugs In India Come From MNCs

Dr Reddy's Founder Anji Reddy Passes Away